Astellas Pharma (4503) Jefferies Global Healthcare Conference 2026 summary

Strategic vision and financial outlook

• Announced a new five-year corporate strategic plan (CSP 2026) focused on sustainable, pipeline-led growth and profitability, aiming for record-high revenues by the mid-2030s through a self-funded strategy.

• Plans to double sales of five strategic brands, shifting to high-margin products, with a pipeline-led inflection point anticipated from FY2029.

• Maintains a disciplined cash allocation strategy, reserving JPY 2 trillion for R&D, JPY 850 billion for strategic investments, and JPY 750 billion for shareholder returns over five years, including a minimum annual 2 Yen dividend increase.

• Strategic brands' revenue share expected to grow from 23% in FY 2025 to over 50% by 2030, improving profitability as these brands are fully owned.

• Board oversight and strong governance ensure strategic alignment and disciplined execution, with renewed corporate values supporting growth ambitions.

Financial performance and outlook

• Achieved record high revenue of JPY 2.1 trillion in FY 2025, with a target of JPY 2.2 trillion in FY 2026 and record revenues by the mid-2030s.

• FY2025 sales revenue reached 2.1T Yen ($14.2B), with a core operating profit margin of 26%.

• R&D expenses averaged 291.8B Yen annually (17.2% of revenue), supporting a robust pipeline.

Research and development and pipeline strategy

• Aims to start 10+ phase III or pivotal studies during CSP 2026, with 5+ within two years and at least 5 by FY2027.

• Employs a Focus Area Approach, integrating biology, modality, and disease to generate multiple projects from four primary focus areas, including immuno-oncology, targeted protein degradation, genetic regulation, and regenerative therapies.

• Pipeline assets are expected to drive growth from FY2029, with revenue potential of JPY 1 trillion in the mid-2030s.

• Introduced a new operating model with empowered cross-functional teams and data-driven decision-making to enhance R&D productivity.